Vertex- Scottish govt. sign cystic fibrosis treatment access contract
Category: #health  | By Mateen Dalal  | Date: 2019-09-14 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Vertex- Scottish govt. sign cystic fibrosis treatment access contract

As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines.

Vertex Pharmaceuticals Incorporated has reportedly announced that Scotland based patients suffering from cystic fibrosis will now be eligible to have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor subsequently after signing an agreement for access.

Ludovic Fenaux, Senior VP, Vertex International, reportedly stated that the company would like to appreciate the Scottish authorities for their partnership and the flexible and collaborative way which helped both of the entities have worked together to figure out an access solution. It means that about 400 eligible patients suffering from cystic fibrosis in Scotland will now be able to have access to SYMKEVI or ORKAMBI, he further added.

Apparently, as part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. This data will further support any future submissions to the Scottish Medicines Consortium (SMC).

Reportedly, Vertex cystic fibrosis medicines have been reimbursed in 17 countries around the world. These 17 countries include Australia, Austria, Denmark, Germany, Italy, the Republic of Ireland, the Netherlands, the U.S. and Sweden.

According to reliable sources, around 900 people in Scotland are suffering from CF. In the United Kingdom, 32 years is the median age of death of people suffering from CF. NHS Scotland has estimated that one in 24 Scots have a CFTR mutation. If this mutation is carried by both parents then it may lead to a baby being born with CF.

For the record, Vertex is a multinational biotechnology firm which invests in innovative initiatives to develop medicines for patients suffering from serious disorders. The company owns three approved medicines which can treat the primary cause of cystic fibrosis (CF).  Cystic fibrosis is a rare and life-threatening genetic disorder. There are several ongoing clinical and research programs going on to develop efficient treatment of CF.

Source Credit:

https://www.businesswire.com/news/home/20190912005349/en/Vertex-Announces-New-Access-Agreement-Scottish-Government

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...